ReviewClinical medicine (London, England)2023
Future therapies for obesity.
Review in Clinical medicine (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 39 citations in OpenAlex.
- Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass.Obesity surgery · 2026Article
- Estimating the Bariatric Surgery Rate in the Potentially Eligible Population within the Brazilian Public Healthcare System, 2017-2023.Obesity surgery · 2026Article
- Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: A real-world observational study.Diabetes, obesity & metabolism · 2026Observational
- Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.The Indian journal of medical research · 2026Review
- Association between body fat percentage and metabolic and hematologic biomarkers in Korean adults.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026Article
- Assessment of cardiopulmonary function: updated two-minute walk distance and walk work equations for obese Chinese populations.BMC pulmonary medicine · 2026Article
- Threonic acid, an ascorbic acid metabolite, synergizes with intermittent fasting to ameliorate obesity.Experimental & molecular medicine · 2026Article
- Analysis of fatty acids concentration in the liver of rats with diet-induced obesity after bariatric surgery and a high-fat/high-sugar diet.Frontiers in physiology · 2026Article
- The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Innovative Therapeutic Approaches Targeting Obesity: Can Flavonoids Improve the Efficacy of Anti-Obesogenic Drugs?International journal of molecular sciences · 2025Review
- Characterization of prevalent genetic variants in the Estonian Biobank body-mass index GWAS.Nature communications · 2025Article
- New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?Reviews in endocrine & metabolic disorders · 2025Review
- Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions.Diabetes & metabolism journal · 2025Review
- Hormonal predictors of the insulin sensitive phenotype in humans.Biomolecules & biomedicine · 2025Article
- Hormonal predictors of the lean phenotype in humans.Biomolecules & biomedicine · 2025Article
- Old and new anti-obesity drugs.Journal of diabetes and metabolic disorders · 2025Review
- The Mechanisms of Chronic Inflammation in Obesity and Potential Therapeutic Strategies: A Narrative Review.Current issues in molecular biology · 2025Review
- Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.Current obesity reports · 2025Review
- Breaking barriers: novel reference equations for the six-minute walk distance and work in obese Chinese adults.Journal of health, population, and nutrition · 2025Article
- What is the pipeline for future medications for obesity?International journal of obesity (2005) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric surgery can lead to sustained long-term weight loss (WL) and improvement in multiple obesity-related complications, but it is not scalable at the population level. Over the past few years, gut hormone-based pharmacotherapies for obesity and type 2 diabetes mellitus (T2DM) have rapidly evolved, and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) as dual or triple agonists are under investigation to enhance and complement the effects of GLP1 on WL and obesity-related complications. Tirzepatide, a dual agonist of GLP1 and GIP receptors, marks a new era in obesity pharmacotherapy in which a combination of gut hormones could approach the WL achieved with bariatric surgery. In this review, we discuss emerging obesity treatments with a focus on gut hormone combinations and the concept of a multimodal approach for obesity management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.